Comments from Dr. Michael Cooney:

One of the decisive factors in our practice choosing to introduce Calmare Therapy was an independent scientific report published by Thomas J. Smith, MD, Endowed Chair of Palliative Care Research and Medical Director, at Virginia Commonwealth University’s Massey Cancer Center. The 2011 study, one of the first detailed studies conducted in the U. S. since Calmare received FDA clearance, concluded, “Patient-specific cutaneous electrostimulation (the Calmare therapeutic process) with the MC5-A Calmare device appears to dramatically reduce pain in refractory CIPN patients with no toxicity.”

Clinical Trial Details with Link:
 
 

<!–

–>Purpose

RATIONALE: Electronic stimulation using a MC5-A Scrambler may help relieve pain in patients who develop peripheral neuropathy while undergoing chemotherapy treatments for cancer.

PURPOSE: This phase II trial is studying how well MC5-A Scrambler therapy works in reducing peripheral neuropathy caused by chemotherapy.